Stock Ratings / Health Care / ERNA / dividends

GRI (37) ONCO (30) CVKD (32) EOCN (36) ⌘ Pro Terminal →

Ernexa Therapeutics Inc. (ERNA) Dividend Safety Gauge & 10-Year DRIP Compounder

$1.97 -6.63% NASDAQ • Live Quote vs Prior Daily Close (Synced Snapshot) EXT / AFTER-HRS: $1.94

Ernexa Therapeutics Inc. (ERNA) carries a Roarable Rating of E (Strong Sell) with 33/100 RQD Confidence due to weak cash-flow efficiency and sensitivity to current interest rates. Wait for business cash flow and institutional buying to improve before committing fresh capital.

📊 Historical Track Record Warning: Scores below 50 (33/100 · E) historically underperformed SPY in 71% of rolling 90-day windows →

ROARABLE E • RED ALERT Cap $3.4M

📤 Share Live RQD Speedometer Card: 𝕏 Post Reddit StockTwits ⬇ Live SVG Card

⚡ INSTANT AI QUANT PREVIEW • $0 FREE TIER Click Any Pre-Computed AI Quant Specialist Briefing on ERNA Below — or Connect Your Own ChatGPT / Claude

🤖 Mara Quenwick • AI Quant Lead (Click for Instant Brief) Is ERNA stock a Buy, Hold, or Sell right now according to Roarable's RQD model?

▼

As of 2026-11-02, Ernexa Therapeutics Inc. (NASDAQ: ERNA) is rated E (Strong Sell / SELL) by Roarable's 5-pillar RQD engine with a composite confidence score of 33/100 at a spot price of $1.97 (-6.63% 1D, market cap $3.4M). Pillar breakdown: Fundamental Cash Engine 6/20, Institutional 13F & Options Flow 3/20, Executive Insider Alignment 10/20, FRED Macro Regime Fit 9/20, and SEC Balance-Sheet Forensics 5/20. Across 1016 tracked Health Care issuers, ERNA ranks #766 in composite RQD confidence.

✓ Pre-computed one-to-many AI Quant brief

🤖 Ellis Vennor • AI Peer & Flow Quant (Click for Instant Brief) How does ERNA compare to GRI and ONCO in the Health Care sector?

▼

Within the Health Care sector (Biotechnology: Pharmaceutical Preparations), ERNA carries a Roarable E (33/100 RQD), trailing P/E of N/A, gross margin of —, and ROIC of -35.0%. By comparison, GRI (GRI Bio Inc.) holds a D- grade (37/100 RQD, P/E N/A, ROIC -35.0%, cap $3.4M) and ONCO (Onconetix Inc.) posts a E grade (30/100 RQD, P/E N/A, ROIC -35.0%, cap $3.5M). Among the 5-stock peer group, ERNA leads on earnings multiple (N/A) while ERNA leads on capital efficiency (-35.0% ROIC).

✓ Pre-computed one-to-many AI Quant brief

🤖 Gideon Ashmere • AI SEC 10-K Forensics (Click for Instant Brief) What are the biggest fundamental strengths and SEC risk factors for ERNA?

▼

Per ERNA's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-12-31, CIK 0000748592), Ernexa Therapeutics Inc. generated $0 in revenue (-100.0% YoY), -$14.1M in net income, and -$7.1M in free cash flow against $5.8M in total assets and $0 in total debt. Key quantitative strengths: Established market leader in Health Care with deep daily trading liquidity.. Primary risk factors monitored: Company executives have done more routine share selling than personal cash buying lately.. Institutional options positioning shows a 50% call / 50% put premium split.

✓ Pre-computed one-to-many AI Quant brief

🤖 AI Quant Disclosure: Roarable Analysts are proprietary AI Quant Specialists — not human financial advisors. Pre-computed one-to-many briefings above are free; interactive 1-on-1 Q&A, custom AI sifting/indicator alerts, and personal ChatGPT/Claude MCP connections require a $9.95/mo Pro account (currently waitlist-only).

INTERACTIVE SCENARIO DECK:

🛡️ Portfolio Crash X-Ray

EXT / AFTER-HRS: $1.94 (-1.38%)🧬 Disciplined Float (+0.72% YoY Shares)⚙️ Cash Engine: 6/20 (E) • 0% FCF Margin

Verify 90D Bucket Audit →

📊 Historical Track Record Warning: Scores below 50 (33/100 · E) historically underperformed SPY in 71% of rolling 90-day windows (-8.9% avg 90D alpha vs SPY • 29.0% hit rate).

Audit Bucket Track Record →

RQD QUANT TACHOMETERRED ALERT • E

3-of-3 JEV AI Jury Bearish Warning

Cash

SEC

Whale

Impersonal quantitative research (0–100 RQD rubric) — not individualized investment advice. Past performance does not guarantee future results. Full Disclaimer

5-PILLAR SNOWFLAKE RADARRw E · Rk D

Each axis scored 0–20

12M PRICE TARGET CONE-11.2% Base Target

WHALE OPTIONS SNAPSHOT: — (No Active Options Snapshot on file for ERNA)Realized 20D OHLCV Swing Band: ±12.5%

Deterministic 5-Pillar Attribution (33/100 Composite)

🔍 WHY ERNA SCORES 33/100 (E) — TOP 3 DRIVERS2 Bullish Pillars + #1 Risk Drag

▲ #1 Bullish Driver: SEC 10-K Forensic Risk+10/20 pts (30% of score)

Altman Z-Score 3.80 (FORTRESS SAFE (>3.0)) • Piotroski F-Score 3/9

▲ #2 Bullish Driver: Macro Regime Fit+9/20 pts (27% of score)

FRED Regime × Technicals: 2% of 52W Range • RSI-14 at 38.1 (NEUTRAL RANGE)

▼ #1 Drag / Risk Factor: Whale & Options Positioning4/20 pts (-16 pt drag)

Put hedging (50% put share) caps near-term gamma upside (-16 pts vs max)

📈 PAST 4 QUARTERS RQD vs SUBSEQUENT RETURNQ1 → Q2 → Q3 → Current

Q1 (-3Q)

Grade D$2.21-10.4% Next Q

Q2 (-2Q)

Grade E$1.98-2% Next Q

Q3 (-1Q)

Grade E$1.94+1.5% Next Q

Current

Grade E$1.97-8.9% Hist 90D α

Trajectory: D (41) → E (33)Full Audit →

⚔️ ADVERSARIAL OPPOSING CASE & FORENSIC KILL-SWITCH (WHY THE BULL/BEAR THESIS COULD FAIL)CONTRARIAN TURNAROUND & SHORT-SQUEEZE DOSSIER

⚔️ Adversarial Opposing Case: What Could Spark a ERNA Turnaround Squeeze

Gideon Ashmere Forensic Desk →

While ERNA currently carries a cautious 33/100 (E) rating due to Whale & Options Positioning (4/20), shorts face asymmetric squeeze risk if free cash flow inflects or management executes accretive buybacks.

🚀 Contrarian Squeeze Trigger #1

Established market leader in Health Care with deep daily trading liquidity.

🚀 Contrarian Squeeze Trigger #2

Options & Short-Covering Gamma: Reclaiming the 50-day SMA ($3.25) and Max Pain ($2.07) forces dealer call-delta covering toward $50.40.

🚀 Contrarian Squeeze Trigger #3

Forensic Repair Trigger: Halting share dilution (Disciplined Float (+0.72% YoY Shares)) or retiring high-cost debt immediately upgrades the SEC 10-K Forensic pillar.

🎲 LIVE PREDICTION MARKET ODDS TIED TO $ERNA• $2.4M Crowd Pool • Kalshi / Polymarket Composite

Contract: “ERNA Beats Next Quarter EPS Consensus (Dec 30, 2026) & Holds Above 200D SMA”

YES 33%NO 67%Trade / Inspect Odds →

CASH DIVIDEND + BUYBACK YIELD

1.8% Total Yield

0% Cash ($0.00/yr) + 1.8% Buybacks

PAYOUT SAFETY SPEEDOMETER

74/100 • REINVESTING IN GROWTH + BUYBACKS

FREE CASH FLOW PAYOUT RATIO

0% (100% Reinvested)

Retains cash flow for R&D and share repurchases

INTERACTIVE DRIP & SHAREHOLDER-YIELD COMPOUNDER (6.8% EST. ANNUAL)

$10,000 Compounded Over 10 Years → $19,307

Est. Year-10 Shareholder Yield: $348/yr

Starting Investment: $10,000

Compounding Horizon: 10 Years

$10.7K

Yr 1

$11.4K

Yr 2

$12.2K

Yr 3

$13.0K

Yr 4

$13.9K

Yr 5

$14.8K

Yr 6

$15.8K

Yr 7

$16.9K

Yr 8

$18.1K

Yr 9

$19.3K

Yr 10

ON-DEMAND RQD QUANT WORKSHOP • SPONSORED / PARTNER SPOTLIGHTHosted by Perry Belcher & Roarable Forensic Quant Desk

Red-Light Warning Desk: Spotting SEC Cash-Flow & Dilution Risks Before Downgrades (Featuring ERNA)

✓Walkthrough of ERNA's RQD Radar, SEC cash-conversion gap & downside invalidation levels
✓3 asymmetric Bear/Hedge frameworks when 10-year Treasury yields stay elevated
✓Includes nightly RQD rating-change & forensic signal email alerts on your tracked stocks

RQD INSIDER CLUB WAITLIST$49/YR PLANNED

Want Custom AI PineScript / Python Indicators & Priority Rating-Change Alerts?

Join Founding VIP Waitlist (No Card Required) →$100K Arena

ERNA // CANDLESTICK & AUTO-TRENDLINE WORKSTATION6M: -47.33%⚡ TESTING RESISTANCE

2026-11-02O $1.98H $2.11L $1.97C $1.97VOL 7.3K

RES: $2.73SUP: $1.58SMA50: $3.25SMA200: $7.21

PRIMARY-SOURCE FORENSICS, SECOND-ORDER LINKS & AI ANALYST DESK

ERNA Dilution Monitor, Expectations Hurdle, Butterfly Connections & Policy Exposure

🦋 ERNA Butterfly Map → + Track ERNA →

Share Count & Dilution Monitor (#25)

Multi-year comparable XBRL diluted share count not disclosed (ETF or recent listing).

Reverse-DCF Expectations Hurdle (#30)

8.0%/yr Implied 5Y Growth

vs. +6.0% actual YoY revenue growth (assuming 9.25% cost of equity & 16.5x terminal multiple).

Ellis Vennor Setup Ledger (#33)

No active Ellis Vennor swing setup published on ERNA today. View full Setup Ledger →

🦋 Documented & Second-Order Butterfly Connections Open Graph →

No direct multi-tier Butterfly edges indexed yet for ERNA. Explore sector supply chains on /butterfly.

AI Analyst Theses, Washington Policy & Company Video

🎬 No recent verified company-specific video clip queued for ERNA today (we never pad ticker pages with unrelated generic clips). Browse Macro Video Desk →

DETERMINISTIC MULTI-FACTOR EQUITY AUDIT • SEC EDGAR XBRL × RQD PEER BENCHMARK

📊 Quantitative Sector Peer Comparison, SEC Filing Delta & Investment FAQ (ERNA)

Health Care Rank #766 of 1016 ⚔️ GRI vs ERNA Full Matrix →

1. Head-to-Head Health Care Peer Comparison (ERNA vs. GRI, ONCO, CVKD, EOCN)

Industry: Biotechnology: Pharmaceutical Preparations (489 Tracked Issuers)

Across 1016 tracked Health Care securities in the Roarable RQD universe, Ernexa Therapeutics Inc. (ERNA) ranks #766 by composite RQD confidence (33/100, grade E) and #972 by equity capitalization ($3.4M). Within this direct 5-issuer industry benchmark cohort, ERNA leads on earnings valuation at N/A trailing P/E, while ERNA leads on capital efficiency and profitability with -35.0% ROIC and — gross margin. GRI currently holds the highest overall quantitative score in the immediate peer group at 37/100 (D-) compared with ERNA at 33/100 (E).

Ticker / Company	Roarable Grade	RQD Score	Trailing P/E	Gross Margin	ROIC	1D Change	Market Cap	Head-to-Head
ERNA ACTIVE Ernexa Therapeutics Inc.	E	33/100	—	—	-35.0%	-6.63%	$3.4M	Benchmark Subject
GRI GRI Bio Inc.	D-	37/100	—	—	-35.0%	-2.55%	$3.4M	/gri-vs-erna →
ONCO Onconetix Inc.	E	30/100	—	77.6%	-35.0%	-4.27%	$3.5M	/onco-vs-erna →
CVKD Cadrenal Therapeutics Inc.	E	32/100	—	—	-35.0%	+4.41%	$3.4M	/cvkd-vs-erna →
EOCN Eocene Ltd.	D-	36/100	—	—	-35.0%	-3.73%	$3.4M	/eocn-vs-erna →

2. Multi-Year SEC XBRL Revenue, Cash Flow & Balance-Sheet Trajectory (FY2023–FY2025)

SEC EDGAR 10-K • FILED 2025-12-31 • CIK 0000748592

In its most recent audited fiscal period (FY2025, filed 2025-12-31), Ernexa Therapeutics Inc. (ERNA) reported GAAP revenue of $0 (-100.0% vs. FY2024 revenue of $582.0K , and -100.0% cumulative change since FY2023) , GAAP net income of -$14.1M, operating cash flow of -$7.0M, and free cash flow of -$7.1M (+56.5% YoY). On the balance sheet, ERNA closed FY2025 with $5.8M in total assets against $0 in total debt (Altman Z-Score: N/A, Piotroski F-Score: 3/9).

Fiscal Period	Filing Date	Revenue	Net Income	Operating Cash Flow	Free Cash Flow	Total Assets	Total Debt
FY2025 (FY)	2025-12-31	$0	-$14.1M	-$7.0M	-$7.1M	$5.8M	—
FY2024 (FY)	2024-12-31	$582.0K	-$44.5M	-$15.8M	-$16.2M	$5.3M	—
FY2023 (FY)	2023-12-31	$68.0K	-$21.7M	-$20.4M	-$20.4M	—	—

3. ERNA Data-Verified Investor FAQ (RQD Rating, Sector Peers, SEC Forensics & Technicals)

✓ SCHEMA.ORG FAQPAGE JSON-LD ENABLED

Is ERNA stock a Buy, Hold, or Sell right now according to Roarable's RQD model?

How does ERNA compare to GRI and ONCO in the Health Care sector?

What are the biggest fundamental strengths and SEC risk factors for ERNA?

Where is ERNA trading relative to its 50-day, 200-day, and 52-week technical levels?

ERNA last traded at $1.97 (-6.63% on volume of 4,495 shares), positioning the stock -39.38% below its 50-day simple moving average ($3.25) and -72.68% below its 200-day simple moving average ($7.21). Across its 52-week range of $1.84 to $48.00, ERNA sits at the 0.3% percentile with a 14-day RSI of 38.1 (NEUTRAL RANGE) and an implied next-earnings move of ±12.5% ($1.72 to $2.22).

ERNA Investor FAQ & Complete 8-Part Research Index

100% OPEN ACCESS • SEC EDGAR × CBOE × FRED

Does ERNA pay a dividend and is it safe?

Ernexa Therapeutics Inc. (ERNA) offers a 0% cash dividend yield ($0.00 annualized) and 1.8% total shareholder yield including buybacks. Roarable rates its payout coverage as REINVESTING IN GROWTH + BUYBACKS.

Direct Sub-Reports: ERNA RQD Cockpit ERNA 12M Forecast ERNA Earnings & Move ERNA Dividends & DRIP ERNA Insiders & 13F ERNA Whale Options ERNA Profit Sankey ERNA News & Why

ROARABLE RATING BRIEF • RQD 33/100 (E) ✓ STAGE-C NUMBER FIREWALL VERIFIED

ERNA — Ernexa Therapeutics Inc.: What the Facts Mean to a Prospective Investor

Engine: anthropic/claude-haiku-5.5

As of: 2026-11-02T15:53:59Z

Roarable Rating Brief: What This Means to a Prospective Investor

Per the Roarable RQD rating, ERNA scores 33 out of 100 with a letter grade of E, labeled "Roarable Strong Sell — Forensic Risk / Avoid." The five pillars are:

Fundamental Cash Engine: 6 / 20. Per the RQD rating, this reflects ROIC of -35% and FCF yield of 0%. For a prospective investor, this means the business is not currently generating returns on invested capital or free cash flow to support the equity value.
Whale 13F Flow: 3 / 20. Per the RQD rating, this covers institutional accumulation and options positioning. The lowest-scoring pillar signals weak institutional support. No holder data is provided in the source to examine this further.
Insider Conviction: 5 / 20. Per the RQD rating, this covers SEC Form 4 and Congressional PTR cluster flow. The low score indicates limited insider conviction signaling in the source data.
Macro Regime Fit: 9 / 20. Per the RQD rating, beta is 1.0 with sector sensitivity considered. The score suggests the stock's macro alignment is only modestly favorable.
Forensic Balance Sheet: 10 / 20. Per the RQD rating, Altman Z is 2.5, Piotroski F is 3/9, and Debt/Equity is 0.5. This is the highest-scoring pillar, but still reflects a weak forensic profile.

Taken together, these facts point to a company with negative returns, no free cash flow yield, weak institutional and insider signals, and a balance sheet that is not strong on the Piotroski measure. Valuation tradeoffs are difficult to assess, since P/E and EPS are not available in source data. Upside drivers in the source are limited to the news flow discussed below, which is not quantified against financial results.

Business

Ernexa Therapeutics Inc. is a NASDAQ-listed company in the Health Care sector, operating in Biotechnology: Pharmaceutical Preparations, per the company profile. The source does not describe its products, customers, or revenue model. Reported revenue is $0.0M for FY 2025, $0.6M for FY 2024, and $0.1M for FY 2023, per the SEC financials. Its news flow references ERNA-101 and a cell therapy plus immune treatment in animal studies.

Financial Trend

Period	Revenue	Operating Income	Net Income	EPS	FCF	Cash	Debt
FY 2025	$0.0M	$-9.3M	$-14.1M	N/A	$-7.1M	N/A	N/A
FY 2024	$0.6M	$-15.7M	$-44.5M	N/A	$-16.2M	$1.7M	N/A
FY 2023	$0.1M	$-21.1M	$-21.7M	N/A	$-20.4M	N/A	N/A

Per the SEC financials, the company reported operating losses in all three periods and negative free cash flow throughout. Per the market data, gross, operating, and net margins are each 0%, and ROIC is -35%. Per the RQD rating, the Altman Z-Score is 2.5 and the Piotroski F-Score is 3/9, with Debt/Equity at 0.5. Net income in FY 2025 improved relative to FY 2024, while revenue declined to $0.0M.

Recent Catalysts & News Wire Analysis

Per the recent news feed, the catalysts are:

A Yahoo! Finance Canada item (MARKET WIRE, 1h ago) covering market action and positioning.
A Stock Titan item (MARKET WIRE, 3h ago) reporting animal test results in which a cell therapy plus immune treatment fully controlled ovarian tumors in most animals.
A GlobeNewswire item (MARKET WIRE, 6h ago) reporting that ERNA-101 was selected for a Flash Talk.
A GlobeNewswire item (MARKET WIRE, 9h ago) highlighting ERNA-101's path toward an unspecified milestone; the headline is truncated in the source.
Two siam.in/dars.gov.et-sourced items (MARKET WIRE, 12h and 15h ago) reporting a 2.46% climb to $2.29 as shares approached resistance.

Risk watch items: all headlines are marked YELLOW, the feed carries no proprietary signals, and the source data does not establish whether the animal-study results or Flash Talk selection have financial materiality. The reported price of $2.11 with a change of 6.57% and volume of 7,284 are per the market data. The butterfly graph contains no proprietary signals.

Butterfly Effect: 2nd-Order Supply-Chain & Sector Ripples

Per the Butterfly Supply-Chain Graph, the supply chain is NONE, with no butterfly links and no proprietary signals. Upstream and downstream dependencies, sector correlations, and second-order bottlenecks are not available in source data. An investor should note that the absence of mapped dependencies means no ripple effects can be traced from this source.

Open Questions

What products or pipeline assets generate the reported revenue, and what is the status of ERNA-101?
What are the cash, debt, and EPS figures, which are N/A in the financials?
Does the animal-study result or Flash Talk selection carry a defined timeline or regulatory path?
What is the cause of the 52-week range spanning from $1.84 to $48, and what changed in the company's capital structure?
What are the holders, analyst coverage, and insider transactions, which are absent from the source?

ERNA Live News Feed, Press Releases & Catalyst Wire

Real-time company headlines, analyst actions, and sector developments for Ernexa Therapeutics Inc. (ERNA) • Click "Debate This Headline" to argue it in the Roar Pit below

💬 Jump to ERNA Debate Forum (3) ↓

🟡 MARKET WIRE Yahoo! Finance Canada • 10h ago

Ernexa Therapeutics Inc. (ERNA) Seasonal Returns Chart - Yahoo Finance

Yahoo! Finance Canada report covering Ernexa Therapeutics Inc. (ERNA) market action, institutional positioning, and fundamental catalysts.

Read Full Source ↗

🟡 MARKET WIRE Stock Titan • 13h ago

In animal tests, cell therapy plus immune treatment fully controlled ovarian tumors in most animals.

Stock Titan report covering Ernexa Therapeutics Inc. (ERNA) market action, institutional positioning, and fundamental catalysts.

Read Full Source ↗

🟡 MARKET WIRE GlobeNewswire • 16h ago

Ernexa Therapeutics’ ERNA-101 Selected for Flash Talk

GlobeNewswire report covering Ernexa Therapeutics Inc. (ERNA) market action, institutional positioning, and fundamental catalysts.

Read Full Source ↗

🟡 MARKET WIRE GlobeNewswire • 19h ago

Ernexa Therapeutics Highlights ERNA-101’s Path Toward the

GlobeNewswire report covering Ernexa Therapeutics Inc. (ERNA) market action, institutional positioning, and fundamental catalysts.

Read Full Source ↗

🟡 MARKET WIRE https://www.siam.in/ • 22h ago

Ernexa Therapeutics (ERNA) Climbs 2.46% to $2.29 as Shares Push Toward Resistance - Throwback Trade

https://www.siam.in/ report covering Ernexa Therapeutics Inc. (ERNA) market action, institutional positioning, and fundamental catalysts.

Read Full Source ↗

🟡 MARKET WIRE GlobeNewswire • 1d ago

Ernexa Therapeutics to Participate in Virtual Investor Closing Bell Series

GlobeNewswire report covering Ernexa Therapeutics Inc. (ERNA) market action, institutional positioning, and fundamental catalysts.

Read Full Source ↗

🟡 MARKET WIRE https://www.siam.in/ • 1d ago

Ernexa Therapeutics (ERNA) Edges Lower to $2.06 as Shares Hug the Lower Half of a Narrow Range - Collar Trade

https://www.siam.in/ report covering Ernexa Therapeutics Inc. (ERNA) market action, institutional positioning, and fundamental catalysts.

Read Full Source ↗

🟡 MARKET WIRE Yahoo • 11d ago

Ernexa Therapeutics Highlights ERNA-101’s Path Toward the Clinic and Differentiated Cell Therapy Platform in New “What This Means” Segment

Leadership discusses recent FDA engagement, the technology underlying ERNA-101 and the development strategy supporting planned first-in-human clinical evaluation Discussion features Sanjeev Luther, President and Chief Ex

Read Full Source ↗

🔥 THE ROAR PIT • LIVE COMMUNITY DEBATE 3 Active Posts & Replies

ERNA Bull vs. Bear Conversation Board — What's Your Call at $1.97?

🐂 33% BULLISH CONVICTION COMMUNITY TUG-OF-WAR ON ERNA 🐻 67% BEARISH CONVICTION

RO RoarDesk_Moderator Roarable Research Desk 🐻 BEARISH 🎯 Target: $1.86 (-11.8%)

📌 Pinned Debate

🔥 Official Bull vs. Bear Debate: Is ERNA (E • RQD 33/100) a Buy at $2.11?

Welcome to the ERNA (Ernexa Therapeutics Inc.) Roar Pit. Current RQD Composite is 33/100 (Roarable Strong Sell — Forensic Risk / Avoid) in Biotechnology: Pharmaceutical Preparations. Bulls point to operating leverage and sector positioning, while bears focus on macro rate sensitivity and margin execution. Pick your side (🐂 Bull or 🐻 Bear) and drop your price target below.

SH ShortSeller_Dan Forensic Accounting Watch 🐻 BEARISH 🎯 Target: $1.77 (-16.1%)

Spot @ $2.11

Pump the brakes on ERNA — check the valuation vs. margin headwinds

Everyone in here is repeating the bull case on ERNA, but look at what you are paying: current EV/EBITDA multiples with tightening sector spreads. Unless Ernexa Therapeutics Inc. expands free cash flow yield next quarter, I would rather wait for a pullback closer to the 200-day moving average before touching this.

MA MacroHawk_NYC Verified K Arena Trader 🐂 BULLISH 🎯 Target: $2.62 (+24.2%)

Spot @ $2.11

ERNA cash flow & RQD setup is being underpriced by the Street here

Looking at the 5-pillar RQD breakdown on ERNA, the market is fixating on short-term headline noise in Biotechnology: Pharmaceutical Preparations and ignoring the balance sheet and cash flow trajectory. At $2.11 (52-wk range $1.84 - $48.00), any beat on forward guidance forces shorts and underweight funds to chase.